文章核心观点 - 公司第二季度每股收益1.14美元,超出市场预期1.10美元,同比增长5.6% [1][2] - 公司第二季度收入为103.8亿美元,超出市场预期,同比增长4.0% [3] - 公司股价今年以来下跌4.9%,低于标普500指数17.2%的涨幅 [4][5] - 分析师预计公司未来业绩表现将低于市场,给予公司卖出评级 [8] 公司表现 - 公司连续4个季度超出市场盈利预期3次 [2] - 公司连续4个季度超出市场收入预期4次 [3] - 分析师预计公司下季度每股收益1.21美元,全年每股收益4.62美元 [9] 行业表现 - 医疗器械行业目前在250多个扎克斯行业中排名前38%,行业前50%公司的表现是后50%的2倍以上 [10] - 同行业公司AtriCure预计第二季度每股亏损0.15美元,收入同比增长15.3%至1.16亿美元 [12]

The stock market is a place where investors buy and sell shares of publicly traded companies. It offers opportunities for individuals and institutions to invest in various sectors of the economy. The market’s performance is influenced by economic conditions, company earnings, and global events. Investing in stocks can provide potential for capital growth and income through dividends. However, it also carries risks, including market volatility and potential loss of investment.The healthcare sector is a signi ...

Abbott  Laboratories NYSE: ABT is a premier buy-and-hold stock because of its foresightful management, quality operation, portfolio, pipeline, cash flow, and capital return. It’s not always a good buy; all healthcare stocks have ups and downs in their cycles, but Abbott is a buy today, no matter how it moves. Abbott Laboratories TodayABTAbbott Laboratories$104.68 +1.96 (+1.91%) 52-Week Range$89.67▼$121.64Dividend Yield2.10%P/E Ratio32.61Price Target$120.18Add to WatchlistAbbott’s stock price trades in a ran ...

销售业绩 - 第二季度销售额达104亿美元，基础业务表现强劲，有机销售增长率达9.3%[3] - 在2024年第二季度，Abbott的Established Pharmaceuticals销售额在报告基础上增长了0.6%，有机基础上增长了8.1%[33] - Key Emerging Markets地区的销售额在报告基础上减少了0.2%，有机基础上增长了8.8%[36] - 在2024年第二季度，Abbott的Medical Devices全球销售额在报告基础上增长了10.2%，有机基础上增长了12.1%[40] - Diabetes Care销售额为16亿美元，同比增长18.4%[45] - 2024年第二季度净销售额为103.77亿美元，同比增长4.0%[66] - 2024年第二季度营业利润为16.69亿美元，同比增长8.2%[68] - 2024年上半年净销售额为203.41亿美元，同比增长3.1%[79] - 2024年上半年营业利润为30.55亿美元，基本持平[81] - 2024年上半年净利润为25.27亿美元，同比下降6.2%[83] - 第二季度营收总额为529百万美元，税前收益为566百万美元，净收益为518百万美元[1] - 第一半年度营收总额为1,024百万美元，税前收益为1,348百万美元，净收益为1,205百万美元[2] - 第一半年度营收总额为1,049百万美元，税前收益为1,114百万美元，净收益为1,015百万美元[3] 新产品及批准 - 新产品Esprit™ below-the-knee系统获得FDA批准，Lingo™和Libre Rio™连续血糖监测系统获得FDA清关[5] - AVEIR双腔(DR)无导线起搏器系统获得CE认证，为治疗心律不齐的患者提供新选择[5] - 2024年上半年，公司宣布了10个新的增长机会，包括新产品批准和新治疗适应症[5] 财务展望 - 调整后的第二季度每股收益为1.14美元，全年2024年每股收益指引为4.61至4.71美元[5] - Abbott预计2024年全年调整后每股收益为4.61至4.71美元[50] 股息及税务 - Abbott宣布每股股息为0.55美元，连续402个季度派息[52] - Abbott已连续52年增加股息支付，并是S&P 500股息贵族指数成员[53] - 2024年税后收入中包括解决与往年相关的各种税务立场问题导致的约25百万美元净税费支出[111] - 2024年税后收入中包括解决与往年相关的各种税务立场问题导致的约35百万美元净税费支出[117] - 2023年税后收入中包括解决与往年相关的各种税务立场问题导致的约40百万美元净税费支出[112] - 2023年税后收入中包括解决与往年相关的各种税务立场问题导致的约62百万美元净税费支出[118] 公司信息 - Abbott在全球160多个国家为人们提供全方位的医疗技术产品[54]

文章核心观点 - 公司在第二季度实现了强劲的基础业务增长,报告销售额为104.77亿美元,同比增长4.0% [2][3] - 公司医疗器械业务表现出色,销售额增长10.2%,其中糖尿病护理、电生理和结构性心脏业务增长均超过10% [54][55][56][57] - 公司全年业绩指引上调,预计全年调整后每股收益将达4.61美元至4.71美元 [3][63] 业务板块总结 营养品业务 - 营养品业务整体销售额增长3.5%,其中成人营养品增长9.9%,儿童营养品增长5.0% [21][22][23] - 美国婴儿配方奶粉业务继续保持市场份额增长 [22] 诊断业务 - 诊断业务销售额下降5.3%,主要受到新冠检测销售大幅下降的影响 [32][33] - 剔除新冠检测销售,诊断业务有5.9%的有机增长,其中核心实验室诊断增长8.8% [33][34] 成药业务 - 成药业务销售额增长0.6%,其中新兴市场业务增长8.8% [43][44] - 心血管、胃肠和中枢神经系统/疼痛管理等治疗领域表现良好 [44] 医疗器械业务 - 医疗器械业务销售额增长10.2%,其中糖尿病护理、电生理和结构性心脏业务增长均超过10% [54][55][56][57] - 多款新产品和适应症的上市为业务增长提供动力 [55]

These stocks don't appeal only to dividend seekers.Stocks that can survive and thrive for long periods -- say, beyond 20 years -- are a special breed. These companies typically display one or several of the following characteristics: innovative abilities, leadership in a major industry, a strong moat, or exciting growth potential. That's not an exhaustive list of traits such corporations can have, but they are among the most important.To find businesses that display them, it can be helpful to start by looki ...

Loading...Loading...Abbott Laboratories ABT is scheduled to release its financial results for the second quarter, before the opening bell on Thursday, July 18.Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.10 per share, up from $1.08 per share in the year-ago period. Abbott expects to post revenue of $10.37 billion. It posted $9.7 billion a year earlier, according to data from Benzinga Pro.On June 14, Abbott declared a quarterly common dividend of 55 cents per s ...

LAS VEGAS, NEVADA - JANUARY 10: An Abbott logo is displayed at the company's booth during CES 2024 ... [+] at the Las Vegas Convention Center on January 10, 2024 in Las Vegas, Nevada. (Photo by Ethan Miller/Getty Images)Getty ImagesAbbott (NYSE: ABT) will report its Q2 2024 results on Thursday, July 18. We expect the company to post revenue of $10.3 billion and earnings of $1.10 on a per share and adjusted basis, broadly aligning with the street expectations. We expect a low single-digit uptick in sales for ...

Over the years, especially the past three, I have become more cautious about the technology sector’s blatant overvaluation. Nevertheless, it is difficult to ignore the capabilities of companies such as Nvidia (NASDAQ:NVDA) and their innovative solutions for AI. Although, in my opinion, the market’s optimism has still led to high valuations. This is why I am shifting my focus to undervalued healthcare stocks as a means of protecting myself from the overvaluation of the technology sector.I think that the heal ...

Abbott Laboratories (ABT) is slated to report its second-quarter 2024 results on Jul 18, before the opening bell.The company posted adjusted earnings per share (EPS) of 98 cents in the last quarter, which topped the Zacks Consensus Estimate by 2.08%. In the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on all four occasions, the average beat being 2.39%.Q2 EstimatesThe Zacks Consensus Estimate for ABT’s second-quarter 2024 revenues is pegged at $10.35 billion. This suggests a 3. ...